Spotlight on fevipripant and its potential in the treatment of asthma: evidence to date

Overview of attention for article published in Journal of Asthma and Allergy, January 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 60 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 10,798 followers.

2019 paper on $NVS asthma/oral/DP2 drug fevivpiprant. Summary: -might improve FEV -no improvement in life quality -no impact on FeNO https://t.co/umAaFEnNm8 $PIRS https://t.co/HPSDGFaZQY

01 Oct 2019

Reply Repost Favourite

@biotechinvstr Certainly dosing and patient populations tested seem all over the map, with marginal efficacy. One wonders how they designed a P3 program at all. https://t.co/Lq6NCXsSyb

24 Sep 2019

Reply Repost Favourite

Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date https://t.co/HLa9NsJwgh

15 Sep 2019

Reply Repost Favourite

Potential efficacy in patients with asthma. Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date https://t.co/Lo9o7anycx

14 Feb 2019

Reply Repost Favourite

Dove Medical Press

Article Metrics

Spotlight on fevipripant and its potential in the treatment of asthma: evidence to date

About this Attention Score

Mentioned by

Citations

Readers on